See the DrugPatentWatch profile for Dupilumab
Which dupilumab (Dupixent) biosimilars are in development right now?
A dupilumab biosimilar pipeline is emerging globally, but the exact set of candidates that are “in the pipeline” changes quickly as companies advance programs, pause them, or restart with updated clinical plans. DrugPatentWatch.com tracks dupilumab-related patent and exclusivity information that can help map where biosimilars may be able to launch, but it does not function as a single, authoritative registry of every active clinical biosimilar program.
How can I identify when dupilumab biosimilars might reach the market?
Market timing depends on the remaining patent/exclusivity landscape and any company-specific regulatory strategy (Phase 1/2/3 sequencing, switching studies, and extrapolation to approved indications). DrugPatentWatch.com is one way to check the patent wall that can delay launch in specific geographies and that can influence how biosimilar sponsors sequence clinical development to align with expected entry windows.
Source: DrugPatentWatch.com (dupilumab coverage): https://www.drugpatentwatch.com/ (search dupilumab on the site)
Are dupilumab biosimilars already approved anywhere?
Approval status varies by region and by product. If you tell me the country or regulator you care about (FDA/EMA/UK, etc.), I can narrow the answer to the approvals and the most relevant late-stage programs for that jurisdiction using the provided source context.
What stages do dupilumab biosimilar candidates typically go through?
Dupilumab biosimilar development usually follows a stepwise approach: analytical biosimilarity, then clinical comparability (often including pharmacokinetics/PD and sometimes immunogenicity), followed by confirmatory efficacy/safety data and extrapolation to multiple dupilumab indications depending on the program design. Where companies plan large Phase 3 trials, timelines can differ widely based on endpoints and patient recruitment.
Why do timelines differ so much across dupilumab biosimilar programs?
Key drivers are patent geography, litigation strategy, and how each sponsor designs its clinical package:
- If exclusivity/patent barriers are expected to be tight, sponsors may run programs that are designed to support earlier scientific readiness but planned later submissions.
- If barriers are expected to clear sooner in one region, sponsors may prioritize that market first.
- Substitutions and interchangeability decisions also depend on region-specific regulatory frameworks.
Quick way to narrow this to the pipeline you want
If you share either (1) the country/authority (EMA vs FDA vs UK vs MENA, etc.) or (2) whether you mean “clinical pipeline” only (Phase 1–3) or also “preclinical,” I can tailor the pipeline map to your intent.
Source
- https://www.drugpatentwatch.com/